Incannex agrees deal with Curia to scale-up manufacture of traumatic brain injury drug

Incannex Healthcare’s chief scientific officer Dr Mark Bleackley tells Proactive it has engaged leading contract research, development and manufacturing company Curia Global Inc to develop and manufacture GMP-grade IHL-216A, its proprietary inhaled drug for the treatment of concussion and traumatic brain injury. Curia will also generate data on the quality and stability of IHL-216A to support future regulatory filings, including a US Food and Drug Administration (FDA) pre-investigation new drug (IND) package and subsequent IND application.

© 2022 The Latest StockMarket News and Interviews